Loading…
Cadrenal Therapeutics, Inc. is projected to decline to $4.57 by 2027, a -7% move from its current price of $4.92. CVKD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.71 | $4.92 | $5.14 | 0.00% |
| May 30 | $4.62 | $4.92 | $5.23 | -0.01% |
| May 31 | $4.56 | $4.92 | $5.31 | -0.01% |
| Jun 1 | $4.51 | $4.92 | $5.37 | -0.01% |
| Jun 2 | $4.46 | $4.92 | $5.43 | -0.02% |
| Jun 3 | $4.42 | $4.92 | $5.48 | -0.02% |
| Jun 4 | $4.38 | $4.92 | $5.52 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.38 | $4.92 | $5.52 | -0.02% |
| Week 2 | $4.17 | $4.92 | $5.79 | -0.05% |
| Week 3 | $4.02 | $4.92 | $6.01 | -0.07% |
| Week 4 | $3.90 | $4.92 | $6.20 | -0.10% |
| Week 5 | $3.79 | $4.91 | $6.37 | -0.12% |
| Week 6 | $3.70 | $4.91 | $6.53 | -0.14% |
| Week 7 | $3.61 | $4.91 | $6.68 | -0.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.
The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. (CVKD) is currently priced at $5.19 per share, and its market capitalization is $15.98M. It ranks 5018 by market capitalization.
The forecast horizon presents a mixed near-term path and a longer bullish trajectory, with the 2026 average at $5.19 and a rising long-term path that reaches a 2050 average of $24.50. The 2050 max lands at $56.36, with a projected ROI of 372.1 and bullish sentiment in the far future.
In the near term, the model projects a transition into stronger upside over the coming years, with notable milestones in the 2029–2050 window and multiple years showing bullish sentiment and higher max prices, indicating meaningful upside potential relative to today. Overall, the outlook suggests a probabilistic path toward higher prices over the long run, tempered by near-term volatility and risk.
A major floor 26.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.2% away) — a key level to hold.
The nearest ceiling, 35.6% above — a clean break opens room to run.
A major ceiling 75.4% above — clearing it would confirm fresh momentum.
Key CVKD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CVKD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.13 | Sell | $5.08 | Sell |
| MA 10 | $5.11 | Sell | $5.19 | Sell |
| MA 20 | $5.58 | Sell | $5.34 | Sell |
| MA 50 | $5.46 | Sell | $5.72 | Sell |
| MA 100 | $6.36 | Sell | $6.65 | Sell |
| MA 200 | $9.14 | Sell | $8.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.72 | Neutral |
| Stoch RSI (14) | 14.23 | Buy |
| CCI (20) | -84.79 | Neutral |
| Williams %R (14) | -92.13 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -19.21 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 7.87 | Buy |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 38.13 | Neutral |
| Momentum (10) | -0.27 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 5.15 | Sell |
| ADX (14) | 14.04 | Neutral |
| ATR (14) | 0.21 | Info |
The 30-day technical picture is Bearish.
RSI14 is 40, indicating momentum that is neither strongly oversold nor overbought. The near-term moving averages show SMA50 at $5.56 and SMA200 at $9.20, painting a mixed trend with resistance above the current price.
Support is listed at $4.79 and resistance at $6.67, with a 30-day price range of $3.85 to $6.99. Annualized volatility sits at 90%, underscoring substantial near-term price swings and risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.25 | $4.92 | $6.13 | 0% | Neutral | |
| $3.41 | $4.57 | $6.60 | -7% | Neutral | |
| $3.72 | $5.21 | $7.93 | +6% | Neutral | |
| $4.86 | $7.10 | $11.24 | +44% | Bullish | |
| $4.60 | $6.96 | $11.41 | +41% | Bullish | |
| $4.44 | $6.96 | $11.75 | +41% | Bullish | |
| $4.78 | $7.73 | $13.40 | +57% | Bullish | |
| $3.89 | $6.48 | $11.50 | +32% | Bullish | |
| $4.03 | $6.91 | $12.55 | +41% | Bullish | |
| $5.29 | $9.32 | $17.26 | +89% | Bullish | |
| $5.46 | $11.00 | $22.16 | +124% | Bullish | |
| $10.54 | $23.43 | $53.13 | +376% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.25 | $4.92 | $5.81 | +0.00% |
| June 2026 | $4.03 | $4.80 | $5.89 | -2.46% |
| July 2026 | $4.07 | $4.90 | $6.15 | +2.20% |
| August 2026 | $4.20 | $5.12 | $6.53 | +4.43% |
| September 2026 | $4.00 | $4.92 | $6.36 | -3.86% |
| October 2026 | $3.71 | $4.60 | $6.01 | -6.52% |
| November 2026 | $3.70 | $4.63 | $6.11 | +0.54% |
| December 2026 | $3.66 | $4.60 | $6.13 | -0.54% |
Click any year to see its month-by-month CVKD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CVKD to range from $4.25 to $6.13 through 2026. The $4.92 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CVKD price prediction for 2027 points to an average of $4.57 (low $3.41, high $6.60) — a potential decline of -7% on today's $4.92. Price action looks broadly range-bound.
In 2028, CVKD is projected to trade between $3.72 and $7.93, averaging $5.21 — a potential gain of +6% from today's $4.92. That is up +14% on the projected 2027 average. A consolidation phase looks the most probable path here.
Cadrenal Therapeutics, Inc.'s 2029 outlook centres on $7.10, within a $4.86 to $11.24 range. That is up +36% on the projected 2028 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2030, CVKD could reach as high as $11.41, with a base case around $6.96 and support toward $4.60 — roughly +41% from $4.92. Buyers look set to stay in control over this stretch.
Expect CVKD to range from $4.44 to $11.75 through 2031. The $6.96 average target implies a +41% move from current prices. That is 0% versus the projected 2030 average. Momentum favours further upside here.
The CVKD price prediction for 2032 points to an average of $7.73 (low $4.78, high $13.40) — a potential gain of +57% on today's $4.92. Buyers look set to stay in control over this stretch.
In 2033, CVKD is projected to trade between $3.89 and $11.50, averaging $6.48 — a potential gain of +32% from today's $4.92. That is -16% versus the projected 2032 average. Momentum favours further upside here.
Cadrenal Therapeutics, Inc.'s 2034 outlook centres on $6.91, within a $4.03 to $12.55 range. That is up +7% on the projected 2033 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, CVKD could reach as high as $17.26, with a base case around $9.32 and support toward $5.29 — roughly +89% from $4.92. Momentum favours further upside here.
Expect CVKD to range from $5.46 to $22.16 through 2040. The $11.00 average target implies a +124% move from current prices. That is up +18% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CVKD price prediction for 2050 points to an average of $23.43 (low $10.54, high $53.13) — a potential gain of +376% on today's $4.92. Momentum favours further upside here.
Investing $1,000 in CVKD today (≈ 203.252033 CVKD) could be worth
$4,761.26
+$3,761.26 (+376%) by 2050 · US Dollar
Based on the average projected CVKD price of $23.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CVKDwould be worth at today's price.
$1,000 invested in CVKD on May 27, 2025 (≈ 70.323487 CVKD) would be worth
$345.99
-$654.01 (-65.4%) today · 0.35× · US Dollar
Based on a CVKD entry price of $14.22 vs. today's $4.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.16 | $953.49 | -4.7% |
| 1 month ago | $5.7 | $863.16 | -13.7% |
| 3 months ago | $8.38 | $587.11 | -41.3% |
| 6 months ago | $9.39 | $524.07 | -47.6% |
| 1 year ago | $14.22 | $345.99 | -65.4% |
| All time (3.4y) ago | $61.8 | $79.61 | -92.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CVKD forecast.
Our base-case forecast reaches $9.80 around 2040.
Implied market cap at $9.80: $30.17M
The multi-year forecast portrays a bullish trajectory starting in the late 2020s and continuing through 2050. The 2026 average price is $5.19, and the 2029 average is $7.47, followed by continued growth to a 2030 average of $7.33 and a 2050 average of $24.50. The corresponding max prices rise to $12.13 in 2030 and to $56.36 in 2050, with a 2030 ROI of 41.3 and a 2050 ROI of 372.1.
From 2029 onward, the forecast repeatedly types in bullish sentiment, with 2032 averaging $8.11 and 2035 averaging $9.86, then higher in 2040 at $11.68. The outlook is cautious about near-term fluctuations (e.g., 2027 average $4.80) but projects strong upside in the long run, driven by a path to higher average prices and larger possible gains. These are estimates, not guarantees, and come with inherent uncertainty and risk.
Tap a question to reveal the answer.
2030 avg $7.33, min $4.79, max $12.13; ROI 41.3; sentiment BULLISH.
Forecasts show near-term neutral to bearish momentum in 2026–2027, turning bullish later, with 2029 avg $7.47 and 2050 avg $24.50; max $56.36 and ROI up to 372.1 by 2050. These are estimates, not guarantees.
Yes. The forecast max price in 2050 is $56.36, which surpasses $50.
Near term sentiment is BEARISH with RSI 40, 30-day range $3.85–$6.99, SMA50 $5.56, SMA200 $9.20, and volatility at 90%.
Current price is $5.19 and market cap is $15.98M.
Cadrenal Therapeutics, Inc. Community Discussion
0Share your Cadrenal Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.